Holen Sie sich die Stockscreener-App
2.59
1.52%
-0.04
Handel nachbörslich:
2.59
Schlusskurs vom Vortag:
$2.63
Offen:
$2.62
24-Stunden-Volumen:
100.87K
Relative Volume:
0.48
Marktkapitalisierung:
$83.99M
Einnahmen:
$875.70K
Nettoeinkommen (Verlust:
$-39.57M
KGV:
-1.9295
EPS:
-1.3423
Netto-Cashflow:
$-33.65M
1W Leistung:
-7.17%
1M Leistung:
+1.97%
6M Leistung:
-15.64%
1J Leistung:
-50.95%
1-Tages-Spanne:
$2.56
$2.69
1-Wochen-Bereich:
$2.56
$2.9599
52-Wochen-Spanne:
$2.22
$5.74
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.59 | 83.99M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World
Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise
Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat
Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com
VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire
Can Vistagen's Innovative Pherine Technology Disrupt the Neuroscience Market? CEO Presents at Major Forum - StockTitan
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
VistaGen’s Earnings Call: Progress and Challenges - TipRanks
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com
VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks
Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks
Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise
Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq
Vistagen Earnings Reveal $88.6M War Chest, Phase 2A Success Fuels Pipeline Momentum - StockTitan
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance
Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com
USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance
Q3 Earnings Preview: Vistagen to Reveal Latest Progress on Breakthrough Pherine Treatments - StockTitan
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - sharewise
Generalized Anxiety Disorder Pipeline 2024: Mechanism - openPR
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain -February 05, 2025 at 08:38 am EST - Marketscreener.com
Vistagen secures patent for non-opioid pain treatment By Investing.com - Investing.com UK
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin - StockTitan
Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 46.2% - MarketBeat
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):